Visceral Leishmaniasis Treatment, Italy

First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change...

Descripción completa

Detalles Bibliográficos
Autores principales: Gradoni, Luigi, Gramiccia, Marina, Scalone, Aldo
Formato: Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2003
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034325/
https://www.ncbi.nlm.nih.gov/pubmed/14720406
http://dx.doi.org/10.3201/eid0912.030178
_version_ 1782197667579822080
author Gradoni, Luigi
Gramiccia, Marina
Scalone, Aldo
author_facet Gradoni, Luigi
Gramiccia, Marina
Scalone, Aldo
author_sort Gradoni, Luigi
collection PubMed
description First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.
format Text
id pubmed-3034325
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-30343252011-02-10 Visceral Leishmaniasis Treatment, Italy Gradoni, Luigi Gramiccia, Marina Scalone, Aldo Emerg Infect Dis Dispatch First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure. Centers for Disease Control and Prevention 2003-12 /pmc/articles/PMC3034325/ /pubmed/14720406 http://dx.doi.org/10.3201/eid0912.030178 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Dispatch
Gradoni, Luigi
Gramiccia, Marina
Scalone, Aldo
Visceral Leishmaniasis Treatment, Italy
title Visceral Leishmaniasis Treatment, Italy
title_full Visceral Leishmaniasis Treatment, Italy
title_fullStr Visceral Leishmaniasis Treatment, Italy
title_full_unstemmed Visceral Leishmaniasis Treatment, Italy
title_short Visceral Leishmaniasis Treatment, Italy
title_sort visceral leishmaniasis treatment, italy
topic Dispatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034325/
https://www.ncbi.nlm.nih.gov/pubmed/14720406
http://dx.doi.org/10.3201/eid0912.030178
work_keys_str_mv AT gradoniluigi visceralleishmaniasistreatmentitaly
AT gramicciamarina visceralleishmaniasistreatmentitaly
AT scalonealdo visceralleishmaniasistreatmentitaly

Ejemplares similares